8-K: NeuroBo Pharmaceuticals Receives FDA Clearance for Phase 1 Obesity Trial of DA-1726

NeuroBo Pharmaceuticals has received FDA clearance for its Investigational New Drug application for DA-1726, a dual-acting drug for obesity, and plans to begin a Phase 1 clinical trial in the first half of 2024.

Summary

• NeuroBo Pharmaceuticals has announced that the FDA has cleared its Investigational New Drug (IND) application for DA-1726.
• DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that targets both glucagon-like peptide-1 (GLP1R) and glucagon receptors (GCGR).
• The company plans to initiate a Phase 1 clinical trial for the treatment of obesity in the first half of 2024.
• Preclinical studies have shown that DA-1726 resulted in superior weight loss compared to semaglutide (Wegovy) and similar weight loss compared to tirzepatide (Mounjaro) in mouse models, while consuming more food.
• The Phase 1 trial will be a randomized, placebo-controlled, double-blind study with single and multiple ascending doses of DA-1726.
• The trial will enroll approximately 45 participants in the single ascending dose (SAD) study and 36 participants in the multiple ascending dose (MAD) study.
• The primary endpoint of the trial is to assess the safety and tolerability of DA-1726.
• Secondary endpoints include the pharmacokinetics (PK) of DA-1726.
• Exploratory endpoints will include the effect of DA-1726 on metabolic and cardiac parameters, fasting lipid levels, body weight, waist circumference and body mass index (BMI).

Sentiment

Score: 8

Explanation: The document is positive due to the FDA clearance and promising preclinical results, indicating a significant step forward for the company's drug development program. The comparison to existing drugs is also a positive sign.

Positives

• FDA clearance of the IND application allows NeuroBo to proceed with Phase 1 clinical trials for DA-1726.
• Preclinical data suggests DA-1726 may have a better tolerability profile than currently available GLP-1 agonists.
• DA-1726 has shown promising weight loss results in preclinical studies, outperforming semaglutide and matching tirzepatide while allowing for more food consumption.
• The Phase 1 trial is designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726.

Risks

• The success of the Phase 1 trial is not guaranteed, and results may not be consistent with preclinical data.
• There are risks associated with the development of new drugs, including potential adverse events and regulatory hurdles.
• The company's ability to execute its commercial strategy and obtain regulatory approval is subject to various risks and uncertainties.
• The company's ability to recruit subjects for its clinical trials is not guaranteed.

Future Outlook

NeuroBo expects to dose the first patient with DA-1726 during the first half of 2024, with an expected data readout in the first half of 2025.

Management Comments

• Hyung Heon Kim, President and Chief Executive Officer of NeuroBo, stated that the clearance of the IND for DA-1726 allows them to proceed with the Phase 1 program for this novel GLP-1 and glucagon dual receptor, a potential new treatment to address the significant obesity market.

Industry Context

The announcement is significant in the context of the growing market for obesity treatments, with DA-1726 potentially offering a new approach with its dual-acting mechanism. The comparison to existing drugs like semaglutide and tirzepatide highlights the competitive landscape and the potential for DA-1726 to gain market share if successful.

Comparison to Industry Standards

• The document compares DA-1726 to semaglutide (Wegovy) and tirzepatide (Mounjaro), both established GLP-1 agonists for weight loss.
• Preclinical results suggest DA-1726 may offer superior weight loss compared to semaglutide and similar weight loss to tirzepatide, while allowing for more food consumption, which could be a significant advantage.
• The Phase 1 trial design is standard for early-stage drug development, focusing on safety, tolerability, and pharmacokinetics, similar to trials conducted by other companies in the space.

Stakeholder Impact

• Shareholders may view the FDA clearance and positive preclinical results as a positive development.
• Employees may be impacted by the increased workload associated with the clinical trial.
• Patients with obesity may benefit from a new treatment option if DA-1726 proves to be safe and effective.

Next Steps

• Initiation of the Phase 1 clinical trial for DA-1726 in the first half of 2024.
• Data readout from the Phase 1 trial is expected in the first half of 2025.

Key Dates

Keywords

DA-1726, Obesity, Clinical Trial, FDA, GLP1R, GCGR, Oxyntomodulin, Weight Loss, NeuroBo Pharmaceuticals, IND